ERBB2 and esophageal adenocarcinoma: The phase III RTOG 1010 trial randomized patients with HER2+ esophageal adenocarcinoma to the CROSS regimen with or without the addition of trastuzumab and found no significant disease-free survival (DFS) benefit [66].